Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/18/21 (What's New)


  • Switches to 3-drug INSTI-based regimens have been favored in recent years due to:
    • High efficacy and tolerability, both as first-line regimens and switch regimens
    • High patient satisfaction following switch
  • Switching to Dolutegravir-Based 3-Drug Regimens
      Switching to Bictegravir/Emtricitabine/Tenofovir AF
        Switching to Raltegravir-Based 3-Drug Regimens

        Action required